Featured Studies Results
Study Type: Treatment
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)
https://www.facingourrisk.org/research-clinical-trials/study/425 /a-study-of-talazoparib-with-or-without-enzalutamide-in-people-with-prostate-cancer-who-have-previously-received-abiraterone-or-darolutamide-talent
Clinicaltrials.gov identifier:
NCT06844383 (https://clinicaltrials.gov/show/NCT06844383)
Treatment
Phase 2 study for metastatic castration-resistant prostate cancer with an HRR mutation
Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back
https://www.facingourrisk.org/research-clinical-trials/study/381 /testing-com701-maintenance-treatment-to-delay-cancer-growth-after-platinum-chemotherapy-for-ovarian-cancer-that-has-come-back
Clinicaltrials.gov identifier:
NCT06888921 (https://clinicaltrials.gov/show/NCT06888921)
Treatment
Study for relapsed platinum-sensitive ovarian cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment
https://www.facingourrisk.org/research-clinical-trials/study/414 /a-study-to-learn-about-the-study-medicine-called-pf-07248144-in-combination-with-fulvestrant-in-people-with-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer-who-progressed-after-a-prior-line-of-treatment
Clinicaltrials.gov identifier:
NCT07062965 (https://clinicaltrials.gov/show/NCT07062965)
Treatment
Phase 3 study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment
A New Drug, DT2216, Combined With Paclitaxel for Recurrent Platinum-Resistant Ovarian Cancer
https://www.facingourrisk.org/research-clinical-trials/study/429 /a-new-drug-dt2216-combined-with-paclitaxel-for-recurrent-platinum-resistant-ovarian-cancer
Clinicaltrials.gov identifier:
NCT06964009 (https://clinicaltrials.gov/show/NCT06964009)
Treatment
Phase 1b study for people with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies
Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)
Treatment
Treatment study for people with advanced or metastatic cancers
A Phase 2 Study of Dostarlimab Immunotherapy in People with Mismatch Repair-Deficient Endometrial Cancer Who Wish to Preserve Fertility
https://www.facingourrisk.org/research-clinical-trials/study/434 /a-phase-ii-study-of-dostarlimab-immunotherapy-in-people-with-mismatch-repair-deficient-endometrial-who-wish-to-preserve-fertility
Clinicaltrials.gov identifier:
NCT04165772 (https://clinicaltrials.gov/show/NCT04165772)
Treatment
Phase 2 treatment study for people with MSI-H or dMMR early-stage endometrial cancer.
Comparing Shorter vs. Standard Radiation for High-Risk Prostate Cancer (High Five)
https://www.facingourrisk.org/research-clinical-trials/study/397 /comparing-shorter-vs-standard-radiation-for-high-risk-prostate-cancer
Clinicaltrials.gov identifier:
NCT05946213 (https://clinicaltrials.gov/show/NCT05946213)
Treatment
Phase 3 treatment study for high-risk prostate cancer
Testing the Drug CX-5461 for Treating Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/431 /testing-the-drug-cx-5461-for-treating-metastatic-solid-tumors
Clinicaltrials.gov identifier:
NCT06606990 (https://clinicaltrials.gov/show/NCT06606990)
Treatment
Phase 1 study for treatment of advanced solid tumors
Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)
https://www.facingourrisk.org/research-clinical-trials/study/389 /using-the-drug-daraxonrasib-in-surgically-removed-pancreatic-cancer-rasolute-304
Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)
Treatment
Phase 3 study for pancreatic cancer treatment after surgery and chemotherapy
Comparing the Targeted Therapy Daraxonrasib With or Without Chemotherapy to Chemotherapy Alone for First-Line Treatment of Metastatic Pancreatic Cancer (RASolute 303)
https://www.facingourrisk.org/research-clinical-trials/study/407 /comparing-daraxonrasib-with-or-without-chemotherapy-to-chemotherapy-alone-for-first-line-treatment-of-metastatic-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT07491445 (https://clinicaltrials.gov/show/NCT07491445)
Treatment
Phase 3 Study for First-Line Treatment of Metastatic Pancreatic Cancer
Testing a New Targeted Therapy ETX-19477 to Treat Advanced Breast, Colorectal Endometrial, Ovarian or Pancreatic Cancer in People with a BRCA2 Mutation (ERADIC8)
https://www.facingourrisk.org/research-clinical-trials/study/432 /testing-a-new-targeted-therapy-etx-19477-to-treat-advanced-solid-tumors-eradic8
Clinicaltrials.gov identifier:
NCT06395519 (https://clinicaltrials.gov/show/NCT06395519)
Treatment
Phase 1/2 treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer
Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning
https://www.facingourrisk.org/research-clinical-trials/study/378 /study-of-a-new-oral-medication-daraxonrasib-after-surgery-to-help-prevent-pancreatic-cancer-from-returning
Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)
Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery
Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery
https://www.facingourrisk.org/research-clinical-trials/study/386 /comparing-two-vaccine-treatments-with-immunotherapy-for-pancreatic-cancer-before-and-after-surgery
Clinicaltrials.gov identifier:
NCT06782932 (https://clinicaltrials.gov/show/NCT06782932)
Treatment
Phase 1b/2 treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment
Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)
https://www.facingourrisk.org/research-clinical-trials/study/371 /comparing-an-investigational-targeted-drug-azd5335-to-standard-treatments-in-people-with-platinumresistant-ovarian-cancer-trevioc01
Clinicaltrials.gov identifier:
NCT07218809 (https://clinicaltrials.gov/show/NCT07218809)
Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle
Clinicaltrials.gov identifier:
NCT05059444 (https://clinicaltrials.gov/show/NCT05059444)
Treatment
Post-treatment study to monitor for recurrence
Comparing an Experimental Drug Puxi-Sam to Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)
https://www.facingourrisk.org/research-clinical-trials/study/370 /comparing-an-experimental-drug-puxi-sam-with-standard-chemotherapy-for-metastatic-endometrial-cancer-bluestarendometrial01
Clinicaltrials.gov identifier:
NCT07044336 (https://clinicaltrials.gov/show/NCT07044336)
Treatment
Phase 3 treatment study for metastatic endometrial cancer
Treating Advanced Solid Tumors with Targeted Therapies Called RAS(ON) Inhibitors Combined With the Targeted Immunotherapy Ivonescimab
https://www.facingourrisk.org/research-clinical-trials/study/408 /treating-advanced-solid-tumors-with-the-rason-inhibitor-daraxonrasib-combined-with-a-targeted-immunotherapy-ivonescimab
Clinicaltrials.gov identifier:
NCT07397338 (https://clinicaltrials.gov/show/NCT07397338)
Treatment
Phase 1/2 treatment study for solid tumors with a RAS mutation
Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)
https://www.facingourrisk.org/research-clinical-trials/study/359 /study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT06841354 (https://clinicaltrials.gov/show/NCT06841354)
Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.